

OKLAHOMA BOARD OF NURSING
2915 North Classen Boulevard, Suite 524
Oklahoma City, OK 73106
(405) 962-1800

Formulary Advisory Council
August 11, 2016
2:30 p.m.
Basement Conference Room, Cameron Building

AGENDA

1. Call to order
 - 1.1 Declaration of a quorum
2. Decision regarding approval of August 13, 2015, meeting minutes (**Attachment #1**)
page 1-7
3. Board Updates: Verbal reports
 - 3.1 Changes to the *Oklahoma Nursing Practice Act*-Jackye Ward
 - 3.2 Changes to the Rules of the Oklahoma Board of Nursing-Jackye Ward
 - 3.3 New Enhanced Nurse Licensure Compact-Jackye Ward
 - 3.4 Other (verbal report only, no discussion)
4. Review *Request to Amend the Formulary* sent August 28, 2015 by Karen Ann Taylor, APRN-CNP, PMHNP-BC.
 - *Request to Amend (Attachment # 2) page 9*
 - *Guidelines for prescribing Clozapine in Schizophrenia* provided by Karen Taylor (**Attachment #2A**) **pages 11-22**
 - *Focus on Clozapine* provided by Karen Taylor (**Attachment #2B**) **pages 23-32**
 - *Highlights/Full Prescribing Information, 12/2014* provided by Karen Taylor (**Attachment #2C**) **pages 33-60**
5. Review of Clozapine Changes
 - *Clozapine Risk Evaluation a Mitigation Strategy Program (REMS)* (**Attachment #3**) **pages 61-65**
 - *FDA Drug Safety Communication, September 2015* (**Attachment #3A**) **pages 67-70**
 - *Clozaril (clozapine HCl) tablets: Safety Labeling Changes Approved by the FDA, September 2015* (**Attachment #3B**) **pages 71-73**
 - *FDA Information on Clozapine, (Attachment #3C)* **pages 75-77**
6. Review and recommendations to the Oklahoma Board of Nursing on revisions to the Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive

Authority, #P-50B (**Attachment #4**) pages **79-80**

- AHFS 2015 Drug Assignment and Reassignments- All circled dates occurred after our last meeting (**Attachment #4A**) pages **81-84**
 - AHFS 2016 Drug Assignments and Reassignments (**Attachment #4B**) pages **85-87**
 - FDA information-Droperidol no longer available (**Attachment #4C**) page **89**
 - *Aristada Medication Guide*-Atypical Antipsychotic 28:16.08.04, same classification as Clozapine (**Attachment #4D**) pages **91-93**
 - *FDA Approves new injectable drug* (**Attachment #4E**) pages **95-96**
 - *FDA Highlights of Prescribing Vraylar*-Atypical Antipsychotic 28:16.08.04, same classification as Clozapine (**Attachment #4F**) pages **97-126**
 - *FDA Highlights of Prescribing Probuphine* (**Attachment #4G**) pages **127-171**
7. Review and recommendations to the Oklahoma Board of Nursing on the Formulary Advisory Council Procedure for Amending the Formulary, #P-50 (**Attachment #5**) pages **173-174**
 8. Council decision regarding election of chairperson and vice-chairperson
 - 11.1 Chairperson
 - 12.2 Vice-Chairperson
 9. Date for next meeting
 10. Adjournment